[go: up one dir, main page]

BR9910296A - Novos análogos graxos para o tratamento de obesidade, hipertensão e gordura no fìgado - Google Patents

Novos análogos graxos para o tratamento de obesidade, hipertensão e gordura no fìgado

Info

Publication number
BR9910296A
BR9910296A BR9910296-0A BR9910296A BR9910296A BR 9910296 A BR9910296 A BR 9910296A BR 9910296 A BR9910296 A BR 9910296A BR 9910296 A BR9910296 A BR 9910296A
Authority
BR
Brazil
Prior art keywords
sub
hypertension
treatment
obesity
analogs
Prior art date
Application number
BR9910296-0A
Other languages
English (en)
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Publication of BR9910296A publication Critical patent/BR9910296A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"NOVOS ANáLOGOS GRAXOS PARA O TRATAMENTO DA OBESIDADE, HIPERTENSãO E GORDURA DO FìGADO". A presente invenção se refere a novos análogos de ácido graxo de fórmula geral (I) CH~ 3~- [CH~ 2~]~ m~- [x~ i~-CH~ 2~]~ n~-COOR, conforme definido no relatório descritivo, que podem ser usados para o tratamento e/ou prevenção da obesidade, gordura no fígado e hipertensão. Além disso, a invenção se refere a uma composição nutricional compreendendo tais análogos de ácido graxo e a um método para redução do peso total ou da quantidade de tecido adiposo em um animal. A invenção também se refere a um método para aperfeiçoar a qualidade de produtos, tais como, carne, leite e ovos.
BR9910296-0A 1998-05-08 1999-04-23 Novos análogos graxos para o tratamento de obesidade, hipertensão e gordura no fìgado BR9910296A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
PCT/NO1999/000135 WO1999058121A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver

Publications (1)

Publication Number Publication Date
BR9910296A true BR9910296A (pt) 2002-01-15

Family

ID=19907879

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9910297-8A BR9910297A (pt) 1998-05-08 1999-04-23 Novos análogos graxos para o tratamento de diabetes
BR9910296-0A BR9910296A (pt) 1998-05-08 1999-04-23 Novos análogos graxos para o tratamento de obesidade, hipertensão e gordura no fìgado

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9910297-8A BR9910297A (pt) 1998-05-08 1999-04-23 Novos análogos graxos para o tratamento de diabetes

Country Status (18)

Country Link
US (4) US6365628B1 (pt)
EP (5) EP1075259B1 (pt)
JP (3) JP5057003B2 (pt)
KR (3) KR100701503B1 (pt)
CN (3) CN1245157C (pt)
AT (5) ATE247464T1 (pt)
AU (4) AU7240398A (pt)
BR (2) BR9910297A (pt)
CA (3) CA2331395C (pt)
DE (5) DE69932645D1 (pt)
DK (3) DK1075258T3 (pt)
ES (3) ES2207253T3 (pt)
HK (3) HK1034912A1 (pt)
NO (3) NO20005463L (pt)
NZ (3) NZ508047A (pt)
PT (2) PT1075258E (pt)
RU (3) RU2221558C2 (pt)
WO (4) WO1999058120A1 (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
EP1220669A4 (en) * 1999-10-13 2004-12-08 Marco A Chacon THERAPEUTIC MEASURE TO IMPROVE THE EFFECT OF A CALORY RESTRICTION
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
KR100983990B1 (ko) * 2002-05-28 2010-09-30 아지노모토 가부시키가이샤 Ａｔｐ 시트르산 리아제의 발현 억제용 의약 조성물
US8178713B2 (en) * 2002-06-20 2012-05-15 Pronovo Biopharma Norge AS Sulfur-containing phospholipid derivatives
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
RU2005106274A (ru) 2002-09-06 2005-11-10 Янссен Фармацевтика, Н.В. (Be) Гетероциклические соединения
CA2499983A1 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Docohexaenoic acid for improved glycemic control
CN100582085C (zh) * 2002-10-10 2010-01-20 耶达研究及发展有限公司 脂肪醇的碱性酯及它们作为抗炎药或免疫调节剂的用途
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
CN1964630A (zh) 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
JP2007522118A (ja) * 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
WO2005119250A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. New intravenous drug administration and blood sampling model in the awake rat
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
CA2574366A1 (en) 2004-07-19 2006-01-26 Thia Medica As Composition comprising plant and/or fish oils and compounds comprising non-oxidizable fatty acid entities
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US7288525B2 (en) * 2004-12-28 2007-10-30 The Research Foundation Of State University Of New York Method for lowering serum homocysteine
WO2006088798A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
JP2008540394A (ja) * 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
EP2724722B1 (en) 2006-10-20 2016-12-07 NeurEndo Pharma, LLC Method of restoring the incretin effect
WO2008053331A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge A/S Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar).
MX2009004337A (es) * 2006-11-01 2009-05-22 Pronova Biopharma Norge As Compuestos lipidos omega-3.
EP2117301A4 (en) * 2007-02-26 2010-04-14 Yeda Res & Dev USE OF LONG-CHAINED ALCOHOL DERIVATIVES FOR THE TREATMENT OF CIRCULAR HAIR LOSS
US7964751B2 (en) * 2007-02-26 2011-06-21 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses
WO2009052182A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
EP2217558A1 (en) * 2007-10-31 2010-08-18 Pronova Biopharma Norge AS New dha derivatives and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
KR101225320B1 (ko) * 2008-04-29 2013-01-22 에프. 호프만-라 로슈 아게 카르니틴-의존성 팔미토일 트랜스퍼라제 2 억제제로서 4-트라이메틸암모니오-뷰티레이트
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
PL2427415T3 (pl) 2009-05-08 2019-09-30 Basf As Wielonienasycone kwasy tłuszczowe do leczenia chorób związanych z dziedziną chorób sercowo-naczyniowych, metabolicznych i zapalnych
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
EA028535B1 (ru) 2010-11-05 2017-11-30 Пронова Биофарма Норге Ас Способы лечения с применением липидных соединений
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
JP6537980B2 (ja) 2013-02-28 2019-07-03 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法
CA3052449C (en) 2013-03-11 2021-10-19 Jan Remmereit Lipid compositions comprising 5, 11, 14-eicosatrienoic acid and conjugated linoleic acids
EP2968568A2 (en) 2013-03-11 2016-01-20 Life Science Nutrition AS Natural lipids containing non-oxidizable fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
EP3215154B1 (en) 2014-11-07 2020-01-29 Regents of the University of Minnesota Salts and compositions useful for treating disease
EP3288550B1 (en) 2015-04-28 2024-06-05 Basf As Structurally enhanced fatty acids containing sulphur for their use in treating non-alcoholic steatohepatitis
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
WO2019083816A1 (en) * 2017-10-23 2019-05-02 Epitracker, Inc. FATTY ACID ANALOGUES AND THEIR USE IN THE TREATMENT OF STATES RELATED TO METABOLIC SYNDROME
AU2018381124B2 (en) 2017-12-06 2024-06-27 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CA3099482A1 (en) 2018-05-23 2019-11-28 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
EP3934639A4 (en) * 2019-03-04 2023-01-11 Epitracker, Inc. FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE DISORDERS, BEHAVIORAL DISORDERS AND CHRONIC PAIN

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
AU6277396A (en) * 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
ATE221324T1 (de) * 1996-11-20 2002-08-15 Nutricia Nv Fette enthaltende ernährungszusammensetzung zur behandlung des stoffwechselssyndroms
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions

Also Published As

Publication number Publication date
RU2221558C2 (ru) 2004-01-20
ES2204142T3 (es) 2004-04-16
KR20010043314A (ko) 2001-05-25
WO1999058121A1 (en) 1999-11-18
WO1999058122A1 (en) 1999-11-18
DE69910559T2 (de) 2004-06-17
NO20005461D0 (no) 2000-10-30
CA2331395C (en) 2008-10-14
KR20010043315A (ko) 2001-05-25
DK1075259T3 (da) 2003-11-03
ATE336239T1 (de) 2006-09-15
JP2002514596A (ja) 2002-05-21
KR100822077B1 (ko) 2008-04-14
CA2331393C (en) 2009-08-11
EP1285652A1 (en) 2003-02-26
WO1999058123A2 (en) 1999-11-18
CN1302204A (zh) 2001-07-04
DE69927805D1 (de) 2006-03-02
EP1285652B1 (en) 2006-08-16
JP4465672B2 (ja) 2010-05-19
EP1075258A1 (en) 2001-02-14
RU2223095C2 (ru) 2004-02-10
RU2219920C2 (ru) 2003-12-27
CA2331408C (en) 2008-10-21
AU761355B2 (en) 2003-06-05
EP1284139B1 (en) 2006-08-02
AU762790B2 (en) 2003-07-03
US20020198259A1 (en) 2002-12-26
JP2002514594A (ja) 2002-05-21
NO20005461L (no) 2001-01-08
NZ508046A (en) 2003-08-29
NO20005462L (no) 2001-01-08
KR100701503B1 (ko) 2007-04-02
AU7240398A (en) 1999-11-29
DE69927805T2 (de) 2006-07-06
DE69932645D1 (de) 2006-09-14
JP5057003B2 (ja) 2012-10-24
EP1075259B1 (en) 2003-07-23
EP1075259A1 (en) 2001-02-14
DE69909775D1 (de) 2003-08-28
CA2331408A1 (en) 1999-11-18
CN1244323C (zh) 2006-03-08
AU4936699A (en) 1999-11-29
HK1034911A1 (en) 2001-11-09
DK1075260T3 (da) 2006-02-06
DE69910559D1 (de) 2003-09-25
KR100701502B1 (ko) 2007-04-02
US6365628B1 (en) 2002-04-02
EP1075260A2 (en) 2001-02-14
KR20010043316A (ko) 2001-05-25
AU5451799A (en) 1999-11-29
EP1075258B1 (en) 2003-08-20
NO20005463D0 (no) 2000-10-30
ATE247464T1 (de) 2003-09-15
CA2331395A1 (en) 1999-11-18
NZ508047A (en) 2003-05-30
ATE334666T1 (de) 2006-08-15
AU762792B2 (en) 2003-07-03
US6441036B1 (en) 2002-08-27
CA2331393A1 (en) 1999-11-18
EP1284139A1 (en) 2003-02-19
CN1300211A (zh) 2001-06-20
ES2251218T3 (es) 2006-04-16
ATE245416T1 (de) 2003-08-15
AU4936799A (en) 1999-11-29
US6417232B1 (en) 2002-07-09
CN1245157C (zh) 2006-03-15
CN1300212A (zh) 2001-06-20
PT1075258E (pt) 2004-01-30
JP2002514595A (ja) 2002-05-21
WO1999058120A1 (en) 1999-11-18
US7026356B2 (en) 2006-04-11
BR9910297A (pt) 2002-01-02
ES2207253T3 (es) 2004-05-16
DE69909775T2 (de) 2004-06-03
NZ508045A (en) 2003-08-29
EP1075260B1 (en) 2005-10-19
HK1034912A1 (en) 2001-11-09
WO1999058123A3 (en) 2000-03-09
DE69932864D1 (de) 2006-09-28
ATE306916T1 (de) 2005-11-15
CN1223343C (zh) 2005-10-19
HK1034909A1 (en) 2001-11-09
DK1075258T3 (da) 2003-12-01
PT1075259E (pt) 2003-12-31
NO20005462D0 (no) 2000-10-30
NO333143B1 (no) 2013-03-18
NO20005463L (no) 2001-01-08

Similar Documents

Publication Publication Date Title
BR9910296A (pt) Novos análogos graxos para o tratamento de obesidade, hipertensão e gordura no fìgado
DE69512797D1 (en) Prostaglandin-synthase hemmer
WO2003082798A8 (es) Compuestos naturales y derivados de éstos para la prevención y el tratamiento de enfermedades cardiovasculares, hepáticas, renales y para aplicaciones cosméticas
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
CO4970765A1 (es) Composiciones de bajo ph que contienen acido para el cuidado personal que exhiben picazon reducida
BR9811099A (pt) Inibidores de urocinase
RS19504A (en) Novel compounds and compositions as cathepsin inhibitors
BR0212899A (pt) Compostos orgânicos
ATE418974T1 (de) Fettsäure-analogen zur behandlung proliferierender hautstörungen
NO20014240L (no) C16-umettede FP-selektive prostaglandinanaloger
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
IL138638A0 (en) Processes for preparing intermediates
BR0214886A (pt) Fenilalquinos
DE59809505D1 (de) Kosmetische mittel
NO960271D0 (no) Tiokarbamoylforbindelser anvendt som mikrobiocider
GB0224306D0 (en) Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
BR0316971A (pt) Fenilalquinas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA QUE O MESMO NAO ATENDE AO ESTABELECIDO NOS ARTIGOS 8O, 13, 24 E 25 DA LPI - LEI 9.279/96

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 12A, 13A E 14A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/28 (2006.01), A23L 33/115 (2016.0